My first-hand experience working with the company developing and manufacturing the AstraZeneca ‘vaccine’
Raises some interesting questions...
AstraZeneca did not develop or manufacture the adenovirus vaccine
I was first involved with the company that developed and manufactured the AZ marketed gene therapy product in 2013. It was in the days of the coalition Government, and it related to a funding call sponsored by Sir Vince Cable, who then had responsibility for the Department for Business, Innovation & Skills.
The call was titled the Advanced Manufacturing Supply Chain Initiative (AMSCI - pronounced am-ski). It had gone through two rounds of applications and no company in life sciences had been successful. When the third round was announced, I was contacted to help out in finding a company to submit a bid, and frame it so that it met the criteria for an advanced manufacturing bid. Below is an earlier post on the subject:
If you had a chance to read, you will know the bid was for Oxford Biomedica (OXB). OXB was located at a site I had worked at as a permanent employee twice before—for British Biotech and OSI Pharmaceuticals …